MIB guides: [89Zr]Zr-DFO-trastuzumab and [64Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging is a research paper published in Molecular Imaging and Biology (2025). On theSindex it has a DataRank of 0.208. It has been cited 3 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: R01 CA244233
NCI NIH HHS
Grant: R21 CA291680
NCI NIH HHS
Grant: R37 CA276498
NIH HHS
Grant: S10 OD030403
National Institutes of Health
Grant: 1R21CA291680-01
S1PR1-targeted PET imaging to predict and monitor response to HER2-targeting antibody-drug conjugates
National Institutes of Health
Grant: 5R01CA244233-03
Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin
National Institutes of Health
Grant: 5R37CA276498-02
Reversing Drug Resistance in Tumors with Clickable Antibody Pairs
FWCI
1.91
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals